Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.

Pharmacogenomics - 1 May 2022

de Lara Danilo Vieira, de Melo Daniela Oliveira, Araújo Silva Lucas Caetano, Gonçalves Thuane Sales, Júnior Lima Santos Paulo Caleb

Abstract excerpt

Pharmacogenetics (PGx) is the relationship between an individual's genetic variations and the response to pharmacological treatment. We chose to perform an overview of reviews on PGx testing-guided treatment for cardiovascular diseases, based on clinically relevant gene-drug pairs. We conducted a search on Medline, Embase and Cochrane Library, from their inception to 18 June 2020. The most studied gene-drug pairs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C9

Share to Pharmacogenetics

Share to Review Literature as Topic

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 35380455
DOI: 10.2217/pgs-2021-0158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.PMID 35380455Read ↗

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).Semantic proximity Read ↗

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.Semantic proximity Read ↗

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Semantic proximity Read ↗

Optimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Cardiovascular pharmacogenomics: current status and future directions.Semantic proximity Read ↗

Pharmacogenomics in Cardiovascular Diseases.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.Semantic proximity Read ↗

Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.Semantic proximity Read ↗

Comparative analysis of point-of-care bedside cyp2c19-testing guided anti-platelet therapy versus conventional therapies for cardiovascular diseases: a systematic review and meta-analysis.Semantic proximity Read ↗

Drug-gene interactions in older patients with coronary artery diseaseSemantic proximity Read ↗

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx GuidelinesSemantic proximity Read ↗

2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.